- Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis2022 | First Faculty of Medicine
- The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 20212023 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis2022 | First Faculty of Medicine
- Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years2021 | First Faculty of Medicine
- Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination2022 | First Faculty of Medicine
- Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis2019 | First Faculty of Medicine
- Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study2019 | First Faculty of Medicine
- Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial2023 | First Faculty of Medicine
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial2012 | First Faculty of Medicine
- New version of criteria of the disease-modifying therapy in relapsing-remitting multiple sclerosis in Czech Republic in comparison with the outcomes in recent clinical trialsPublication without faculty affiliation
- Risk of secondary progressive multiple sclerosis: A longitudinal study2020 | First Faculty of Medicine
- The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis2016 | First Faculty of Medicine
- Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use2015 | First Faculty of Medicine
- Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis2009 | First Faculty of Medicine
- Real-world operation of multiple sclerosis centres in Central-Eastern European countries covering 107 million inhabitants2023 | First Faculty of Medicine
- Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study2023 | First Faculty of Medicine
- Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison2014 | First Faculty of Medicine
- Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom2022 | First Faculty of Medicine
- Internal comorbidities and complications of multiple sclerosis therapy - don't be caught off guard!2023 | First Faculty of Medicine
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis2018 | First Faculty of Medicine
- Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis2009 | Publication without faculty affiliation
- Interdisciplinary approach to diagnosing adult-onset Niemann-Pick disease type C2016 | First Faculty of Medicine
- Early high efficacy mulitple sclerosis treatment: therapeutic success despite safety barriers2023 | First Faculty of Medicine
- The risk of secondary progressive multiple sclerosis is geographically determined but modifiable2023 | First Faculty of Medicine
- Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases-An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)2021 | First Faculty of Medicine
- Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study2012 | Second Faculty of Medicine
- Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study2019 | First Faculty of Medicine
- Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia2021 | First Faculty of Medicine, Faculty of Physical Education and Sport, Faculty of Medicine in Pilsen, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study2019 | First Faculty of Medicine
- Factors associated with treatment escalation among MS specialists and general neurologists: Results from an International cojoint study2022 | First Faculty of Medicine